--- title: "Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) stock" url: "https://aibio.space/companies/actinium-pharmaceuticals-delaware/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ATNM class action news: Actinium securities class action dismissed with prejudice; plaintiffs file appeal. Actinium Pharmaceuticals, Inc." --- ATNM Actinium Pharmaceuticals, Inc. (Delaware) AMEX · United States # Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) news ATNM class action news Legal · 2026-10-15 ## [Actinium securities class action dismissed with prejudice; plaintiffs file appeal](https://aibio.space/news/actinium-securities-class-action-dismissed-prejudice-plaintiffs-file/) The case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations. ## Latest Actinium Pharmaceuticals, Inc. (Delaware) news We have not published a story on Actinium Pharmaceuticals, Inc. (Delaware) yet. When there is news, it will appear here. ## Actinium Pharmaceuticals, Inc. (Delaware) at a glance - **Ticker**: ATNM - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $36.5 million ### Related companies - [NOVACCESS GLOBAL INC.](https://aibio.space/companies/novaccess-global/) OTC: XSNX - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) NASDAQ: OCUL - [LB Pharmaceuticals](https://aibio.space/companies/lb-pharmaceuticals/) NASDAQ: LBRX - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [Cingulate](https://aibio.space/companies/cingulate/) NASDAQ: CING - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) NASDAQ: TENX - [Genelux](https://aibio.space/companies/genelux/) NASDAQ: GNLX ### Also on AMEX - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) EDVA - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) NSRX - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) RGNT - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX ## What Actinium Pharmaceuticals, Inc. (Delaware) does Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. It takes a biology-driven approach to develop first-in-class radiopharmaceutical therapeutics built on tumor biology and radiochemistry. Its solid tumor candidate, ATNM-400, targets a novel antigen that does not target PSMA, and the company reports pre-clinical activity across metastatic castration-resistant prostate cancer, non-small cell lung cancer and breast cancer. Actimab-A is a CD33-targeted therapy that depletes myeloid derived suppressor cells and is being studied in multiple solid tumors in combination with immune checkpoint inhibitors. The company also develops Actimab-A as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute. Its two conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapies, are CD45-targeting. The company describes Actimab-A and Iomab-B as Phase 2/3 ready assets, and says Iomab-B has FDA alignment on a Phase 2/3 trial design in relapsed or refractory AML. | Product or program | What it is | Stage | |---|---|---| | ATNM-400 | Radiotherapy against a novel non-PSMA antigen for prostate, lung and breast cancer | Pre-clinical activity demonstrated | | Actimab-A | CD33-targeted therapy for solid tumors, AML and MDS | Phase 2/3 ready | | Iomab-B | CD45-targeting conditioning agent for bone marrow transplant | Phase 2/3 ready; FDA alignment on trial design | | Iomab-ACT | CD45-targeting conditioning agent for cell and gene therapies | | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm). ## Actinium Pharmaceuticals, Inc. (Delaware) annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$90,000](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | | | Research and development | [$21.1 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | [$30.0 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | | Net income (loss) | [-$33.9 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | [-$38.2 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | | Cash from operations | [-$24.6 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | [-$33.1 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | | Cash and equivalents | [$48.0 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026086769/) | [$72.9 million](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $36.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Actinium Pharmaceuticals, Inc. (Delaware) Is there a class action against Actinium Pharmaceuticals, Inc. (Delaware)? Our latest story on this, dated Oct 15, 2026: "Actinium securities class action dismissed with prejudice; plaintiffs file appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/actinium-securities-class-action-dismissed-prejudice-plaintiffs-file/). What is the ticker symbol of Actinium Pharmaceuticals, Inc. (Delaware)? Actinium Pharmaceuticals, Inc. (Delaware) trades under the ticker ATNM on AMEX. Where is Actinium Pharmaceuticals, Inc. (Delaware) listed? Actinium Pharmaceuticals, Inc. (Delaware) is listed on AMEX. Our directory also records these other listings: GETTEX:7AY1; LS:A2QA48; LSX:A2QA48. What is the SEC CIK of Actinium Pharmaceuticals, Inc. (Delaware)? The SEC Central Index Key (CIK) for Actinium Pharmaceuticals, Inc. (Delaware) is 1388320. Its filings are on SEC EDGAR. How many shares does Actinium Pharmaceuticals, Inc. (Delaware) have outstanding? 31,441,436 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Actinium Pharmaceuticals, Inc. (Delaware) listed under? Our directory records Actinium Pharmaceuticals, Inc. (Delaware) under United States. What does Actinium Pharmaceuticals, Inc. (Delaware) do? Our directory classifies Actinium Pharmaceuticals, Inc. (Delaware) as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Actinium Pharmaceuticals, Inc. (Delaware)? The ISIN recorded for Actinium Pharmaceuticals, Inc. (Delaware) is US00507W2061. Does aibio.space cover Actinium Pharmaceuticals, Inc. (Delaware)? aibio.space lists Actinium Pharmaceuticals, Inc. (Delaware) among 2,820 public biotech companies and publishes its news here as stories appear. Where is Actinium Pharmaceuticals, Inc. (Delaware) incorporated? SEC records list its state or country of incorporation as DE. What does Actinium Pharmaceuticals, Inc. (Delaware) develop? Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies. It takes a biology-driven approach to develop first-in-class radiopharmaceutical therapeutics built on tumor biology and radiochemistry. What is ATNM-400 from Actinium Pharmaceuticals, Inc. (Delaware)? ATNM-400: Radiotherapy against a novel non-PSMA antigen for prostate, lung and breast cancer Stage: Pre-clinical activity demonstrated. What is Actimab-A from Actinium Pharmaceuticals, Inc. (Delaware)? Actimab-A: CD33-targeted therapy for solid tumors, AML and MDS Stage: Phase 2/3 ready. What was Actinium Pharmaceuticals, Inc. (Delaware)'s revenue last year? $90,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Actinium Pharmaceuticals, Inc. (Delaware) profitable? Actinium Pharmaceuticals, Inc. (Delaware) reported a net loss of $33.9 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Actinium Pharmaceuticals, Inc. (Delaware) Members talk about Actinium Pharmaceuticals, Inc. (Delaware) (ATNM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Actinium Pharmaceuticals, Inc. (Delaware), newest first. Each line links the filing it comes from. 1. 2026-10-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390026109884/ea030854201ex99-1.htm) 2. 2026-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea030189001ex99-1.htm) 3. 2026-05-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea029269101ex99-1.htm) 4. 2025-08-08 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390025073743/ea0249439-10q_actinium.htm) 5. 2025-05-09 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390025041582/ea0241600-8k_actinium.htm) 6. 2025-05-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390025041614/ea0239143-10q_actinium.htm) 7. 2025-03-31 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1388320/000121390025026371/ea0232395-10k_actinium.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:ATNM on TradingView](https://www.tradingview.com/symbols/AMEX-ATNM/). ## SEC filings and registration - **SEC name**: Actinium Pharmaceuticals, Inc. - **CIK**: 1388320 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ATNM (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017 - **Phone**: (646) 677-3870 - **Shares outstanding**: 31,441,436 as of 2026-08-06 (10-Q filed 2026-08-07) - **Former names**: Cactus Ventures, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1388320/000121390026110022/ea0306048-01.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1388320/000121390026109884/ea0308542-8k_actinium.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea0301890-8k_actinium.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1388320/000121390026086769/ea0298254-10q_actinium.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1388320/000121390026070193/ea0295259-8k_actinium.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1388320/000121390026053980/ea0286467-10q_actinium.htm) filed 2026-05-08 - [10-K](https://www.sec.gov/Archives/edgar/data/1388320/000121390026036504/ea0279291-10k_actinium.htm) filed 2026-03-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001388320), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Actinium Pharmaceuticals, Inc. (Delaware) is a public biotech or pharmaceutical company listed on AMEX under the ticker ATNM, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Actinium Pharmaceuticals, Inc. (Delaware) - **Ticker**: ATNM - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00507W2061 - **Other listed symbols**: GETTEX:7AY1; LS:A2QA48; LSX:A2QA48 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-ATNM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/actinium-pharmaceuticals-delaware/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) stock", 2026-10-31, https://aibio.space/companies/actinium-pharmaceuticals-delaware/